Abstract
New biomarkers are currently under development for acute kidney injury and chronic kidney disease. Panels of validated biomarkers are most likely to be required to obtain information that will help in delineating acute versus chronic disease, the pathogenetic nature of the process, the severity, and the capacity for reversibility. Glycoprotein non-metastatic melanoma protein-b, a protein associated with regulation of inflammation and autophagy, is in an intermediate stage of development as a kidney injury biomarker.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
